text:
Celexa/Lexapro... Or Your Money Back
Not for use in children and adolescents
Celexa [citalopram] and Lexapro [escitalopram] are two antidepressants in the family of SSRi's. Some would argue [I'm one of them] that both antidepressants are pretty much the same. Let's face it, Lexapro only ever came to market because the patent was running out on Celexa.
Forest Labs, the manufacturer, have argued that the two drugs differ, maybe so but the end result is the same particularly when it's been down to the marketing team of Forest Labs.
Once again, kids have been targeted despite these group of drugs bearing warnings that they were not recommended for pediatrics.
How do we know this for sure?
Well, in 2010 Forest Labs settled with the US government. Forest Labs were accused of illegally promoting Celexa for use in children and adolescents despite the fact it had not been approved for marketing in the United States.
In other words, they were promoting the use of Celexa in kids to doctors through "off-label" marketing.
We know how that works, right?
Kickbacks, holding back negative study results, ghostwritten papers, in general bending the law to suit their needs.
Forest Pharmaceuticals, a subsidiary of Forest Labs, also pled guilty to a whole range of underhand practices including misbranding Celexa by marketing it for use in children from 1998 to 2002.
With these two settlements Forest Labs and Forest Pharmaceuticals have paid out a wad of cash, moved on and now, it seems, it's business as usual.
But there's one final twist in the Forest saga.
Both Forest Labs and Forest Pharmaceuticals, because of their illegal promotion, now may have to reimburse the families of those who paid for prescriptions of Celexa and Lexapro. Rightly so too.
A consumer fraud class action is underway, meaning that if you as a parent of a child who took Celexa or Lexapro can claw back what you paid. Quite a hefty amount if your child was on either drug for a long time.
These types of consumer fraud cases need a lead plaintiff, someone that not only represents their child or children but one who represents the whole class action. It's like a lead case. Classic example here being the Kilker V GlaxoSmithKline case. Lyam Kilker was born with heart defects as were 800 other kids. Kilker et al represented the class action, they won the case against Glaxo which meant Glaxo settled the majority of other cases.
The Forest lawsuit is looking for additional class representatives. There are already some lead cases in places for many of the US states but more are needed. I'm pretty sure those that represent a group action are compensated handsomely, and why not - putting yourself out front deserves to be rewarded.
I think it's important to keep the pressure on Forest. Settling with the government is one thing, now it's time to settle with the people they duped - the public.
A cynic would suggest that this is just about the dollar, they'd be wrong. This is about getting your teeth into a pharmaceutical company and biting them so hard that they think twice about doing any dirty deeds again.
If I had my way I'd put those responsible behind bars, to promote something that is harmful to any human is wrong, to promote it for children is despicable and abhorrent. Sadly, the only way to hurt big bad pharma is in the pocket and media.
Forest have made two settlements, they should now cough up to those who matter, the parents who forked out money for weekly prescriptions of Celexa and Lexapro.
The fact that some kids never experienced any adverse reaction is irrelevant here. The fact is both Forest Labs and Forest Pharmaceuticals played Russian roulette with children and for that two things should happen.
1. They should be held accountable.
2. They should compensate those they played Russian roulette with.
Both Forest Labs and Forest Pharmaceuticals made huge profit from Celexa and Lexapro, they did so by basically using children as guinea pigs, they did so by wining and dining doctors so they would prescribe more Celexa and Lexapro to children, they did so by withholding negative data about both drugs, data that showed that Celexa was no more effective than placebo for pediatric use.
Why should any company, be they pharmaceutical or a fizzy soda drinks company benefit from putting children's lives at danger?
So, did you or do you know anyone that paid for prescriptions for their children and/or adolescents for Celexa and Lexapro between 2001 and the present day? If so, then you may want to represent a class action in your state.
You can find out more information by calling 800-827-0087 or by filling in an online form HERE.
Forest Labs and Forest Pharmaceuticals should not benefit from your purse, particularly when the products they promoted for children and adolescents were actually dangerous for this vulnerable population. Their shareholders should not benefit from your purse either, namely, Wellington Management Company, LLP, Icahn Associates Corp and many more.
The full complaint can be read, in PDF form, HERE.
JOIN THE FIDDAMAN BLOG ON FACEBOOK
Labels: Baum Hedlund, Celexa, children, citalopram, Class Action, compensation, Escitalopram, Forest Labs, Forest Pharmaceuticals, Lexapro, pediatrics
Canadian Network Report on Big Bad Pharma
Well worth watching.
As usual the pharmaceutical companies mentioned (Eli Lilly, Pfizer and GlaxoSmithKline) in the 16×9 investigation failed to appear in front of camera, opting instead for the tired old "Our drugs are safe and effective" kind of statement.
The regulators come under fire too. Footage includes Pete Breggin and David Healy.
Good to see Canadian TV highlighting the flaws of antidepressants... only wish their limp-wristed regulator, Health Canada, were the same.
**If you can't get the video player to load you can watch it via the TV network [HERE]
Labels: Agitation, antidepressants, Canada, Canadian TV, ELI LILLY, Fraud, GLAXOSMITHKLINE, Homicide, Paxil, Pfizer, Prozac, Violence, Zoloft
Glaxo Add to Their List of Misdemeanours
GSK's addictive antidepressant, Seroxat
One would have thought that British pharmaceutical giant would still be licking their wounds after the record fine of $3billion they dished out a couple of months ago.
No sooner had that particular scab healed Glaxo find themselves [once again] in hot water.
And it's Seroxat that rears its ugly head [once again]
This time Glaxo haven't been accused of pushing it on kids via ghostwritten articles or Madonna tickets for doctors... they've been accused of not allowing other companies to get in on their act.
How did they do this?
I'll explain.
When Seroxat first hit Britain it did so for only a limited time. When pharmaceutical companies bring a drug to market they have the sole rights to that drug until their patent expires. Then, and only then, can other pharmaceutical companies come along and use the compound [paroxetine]. Pharmaceutical companies don't like this so are always devising ways to extend their patent. A clinical trial that tests the drug in kids will give them that extension and increase profits.
So, Glaxo's patent for Seroxat was coming to an end. Three other pharmaceutical companies were waiting in the wings to produce a generic version of Seroxat, a version that would be sold at a much cheaper price and therefore hitting Seroxat [manufactured solely by GSK] sales.
So here's what Glaxo did [ahem allegedly]
Glaxo made "substantial payments" to Alpharma, Generics UK and Norton Healthcare to stop them releasing version of its paroxetine. This would have meant that Glaxo would have been able to profit from the sale of Seroxat and, at the same time, would have meant that their shareholders and investors would have been kept sweet.
Who accuses them of this?
Well, it's not an activist blogger, it's The Office of Fair Trading [OFT] whose job is to make sure that consumers have as much choice as possible across all the different sectors of the marketplace.
In a statement the OFT "alleges GlaxoSmithKline (GSK) concluded agreements which infringed competition law with each of Alpharma Limited (Alpharma), Generics (UK) Limited (GUK) and Norton Healthcare Limited (IVAX) ('the generic companies'), over the supply of paroxetine in the UK. The OFT also alleges GSK's conduct amounted to an abuse of a dominant position in the same market."
The statement adds:
"The OFT's provisional view is that these agreements included substantial payments from GSK to the generic companies in return for their commitment to delay their plans to supply paroxetine independently."
GSK making substantial payments around Seroxat, surely not.
The allegations in this case concern so called 'pay for delay' agreements, where a manufacturer of branded pharmaceuticals, in this instance GlaxoSmithKline, makes payments to a generic company in return for that generic company agreeing to delay its independent entry into the market for a product, in this instance paroxetine.
Glaxo have responded in usual style. A statement on the GSK website stresses that "GSK supports fair competition and we very strongly believe that we acted within the law"
No mention or excuse that this was just part of an era.
Here's how the BBC broke the news.
Jensen Button and the McLaren team must be wondering if the sponsorship deal with Glaxo was such a great idea after all. [Back story]
Some of the major GSK shareholders today include Dodge & Cox Stock, Vanguard PRIMECAP Inv and the Royal Bank Of Canada.
Labels: Alpharma, Andrew Witty, Dodge and Cox Stock, Generics UK, GLAXOSMITHKLINE, gsk, Illegal, Norton Healthcare, OFT, Paroxetine, Royal Bank Of Canada, Seroxat, Trading, Vanguard PRIMECAP Inv
Paxil Birth Defects... (They Knew)
Today I am going to revisit a Paxil birth defect case from 2009.
What makes this case unique is that court documents were made available, giving us all an insight into how trial lawyers operate and how unsealed evidence proved to be the downfall of British pharmaceutical giant, GlaxoSmithKline.
I'm going to focus on the opening statements that were read to the jury by the plaintiffs attorney. The purpose of an opening statement is for an attorney to tell a jury what he/she expects the evidence to show.
The case, LYAM KILKER, a Minor, by MICHELLE M. DAVID, as Next Friend and Individually VS. SMITHKLINE BEECHAM CORPORATION d/b/a GLAXOSMITHKLINE, astounded many as little by little the truth came to the surface regarding Paxil's propensity to cause birth defects.
Lyam Kilker was born with heart defects. His mother, Michelle David, had taken Paxil during her pregnancy.
13 Courtroom 253, City Hall
Sean Tracey of the Tracey Law Firm [Attorney for Kilker]
Glaxo were represented, as usual, by King & Spalding
To set the scene, in other words, to make this more humane than (as it turned out through the verdict) inhumane. Sean Tracey introduces both Lyam and his mom to members of the jury.
MR. TRACEY: May it please the Court, good morning.
JURORS: Good morning.
MR. TRACEY: I am going to reintroduce myself. My name is Sean Tracey. I represent Michelle David and Lyam Kilker. Before I begin, I want to reintroduce to you Jamie Sheller here, and there are a couple young lawyers up front here. Scott Love and Adam Peavy you are going to see wandering around and probably hearing from during this trial. Who you haven't met are my clients. This is Michelle David. Michelle, will you stand up. This is Michelle David. Over here with Michelle's mother is Lyam Kilker. Lyam is here with his grandmother. Lyam is going to stay a few minutes, then I think his grandmother is going to take him out of the courtroom.
Next we see Tracey explain to the jury the injuries caused to Lyam Kilker.
MR. TRACEY: This is the time for me to talk to you about what I believe the facts are going to be, what I think the evidence that comes in during this trial is going to be through the witness stand starting this afternoon, and through the documents that I have obtained as a result of this lawsuit. And so I want to start that by, this is the name of the case, as you have heard, Kilker versus GlaxoSmithKline. And Lyam Kilker, this is going to be undisputed, Lyam Kilker was born October 24, 2005. And shortly after he was born, Michelle found out he had been born with a series of congenital heart defects. During the time Michelle was pregnant, before she was pregnant, she was taking Paxil. She was on Paxil for her first trimester. Now, Lyam, after he was born, was at the hospital and he was diagnosed and his heart defects, there really are three. One is called the ventricular septal defect. One is called an atrial septal defect. Those are holes on the inside of the heart in the walls that separate the four chambers of the heart. The other heart defect he had is something called an interrupted aortic arch. The aorta, where it is supposed to curve, doesn't fully develop. And so what he has is three different, distinct heart defects, each of them related to the failure of his heart to fully develop.
Tracey then goes on to explain to the jurors about the FDA pregnancy categories.
MR. TRACEY: The first one is pregnancy Category A. Are there adequate and well-controlled studies? Are there human studies that demonstrate there is no risk to the fetus? If it is Category A, you can take this drug with impunity and you don't have to worry about children, you don't have to worry about if she gets pregnant. You will learn during this trial that, I think, over 50 percent of pregnancies in the United States are unplanned. Women aren't planning on getting pregnant. That's why these categories can be so important. You don't just consider these categories when you have a woman who is planning a pregnancy. It is any woman of childbearing years who may become pregnant. The evidence in this case is going to be that GlaxoSmithKline knew that over 50 percent of the women in the United States became pregnant without trying to, they were unplanned pregnancies. They knew this back in the 1990s. So Category A, no problems.
Category B, we have done animal studies, doesn't look like there is any problems. Animal studies have failed to demonstrate a risk to the fetus, but we don't have any human studies.
Category C is, we have done animal studies, we have done animal studies, and the animal studies have shown an adverse effect on the fetus, but we don't have any human studies at all.
Category D is, there is positive evidence, there is positive evidence of human fetal risk based on a number of different things, either adverse reaction data from investigations they do or adverse marketing data from women and doctors reporting problems with the drug or from studies. And in that case in a Category D drug you do not prescribe that drug to women of childbearing age with one exception. If the doctor decides that the benefit to the patient is worth the risk to the fetus, then the drug can be prescribed. Doctor Healy, who is a psychiatrist and neuropyschopharmacologist who is going to testify this afternoon, will explain that there may be times when the disease is so serious that it may be worth the risk to the doctor and the patient if there is a life-threatening illness. If somebody is capable of harming themselves or others, they may make the decision to prescribe the drug if, there is no alternatives.
Category X is, we don't care what the benefits are. You do not give this drug to a woman unless she has a pregnancy test that shows she is not pregnant.
Tracey adds:
MR. TRACEY: In 2004 when Michelle David was prescribed this drug, it was a pregnancy Category C, and GlaxoSmithKline says their animal studies have revealed no evidence of teratogenic effects.
Tracey then explains to the jury the process of human development.
MR. TRACEY: In human development when women get pregnant, what you are going to learn and understand is that the most vulnerable time to the human fetus is from weeks 3 to weeks. That is when the fetus is dividing and growing and is the most susceptible to something called a teratogen to a drug that can cause a birth defect. During weeks 3 through 8 the body is rapidly, rapidly expanding, rapidly developing. Cells are being signalled to go to where they are supposed to go. The heart is developing by week 8. By week 8 the heart, from a cellular perspective, is almost completely developed, and there is nothing you can do after that to prevent the heart, to prevent a heart defect if it has already occurred. The importance of this is that when women don't know or aren't planning on becoming pregnant, many times, most of the time, by the time the woman finds out she is pregnant, the damage has been done. This is when in this time frame, weeks 3 to 8, almost every congenital abnormality -- that is a fancy word for a birth defect -- almost every congenital abnormality happens during this time frame.
Tracey goes on to explain to the jury what a teratogen is. In a nutshell, a teratogen is any agent or factor that induces or increases the incidence of abnormal prenatal development.
Enter Dr Sloot
MR. TRACEY: So during the course of this trial you will hear about teratogens and teratogenicity and you will find out about whether Paxil is a teratogen. And one of the ways you are going to learn about this is through a study, an animal study, an animal study done by a doctor named Sloot. Doctor Sloot is a European doctor who works for another pharmaceutical company called Shearing Plough. Shearing Plough is a pretty big company. You may have heard of it. In May of this year, 2009, a study was published by Doctor Sloot. The study said this. What Doctor Sloot did is, he took Paxil and all the other reuptake inhibitors and he exposed rat fetuses to these 12 different drugs, including Paxil. And what Shearing Plough was trying to figure out, what they were trying to do was figure out whether one of the drugs that they were going to put on the market to compete with GSK's drug was capable of causing birth defects. And so they took the drug they were going to take to market, and before they took it to market, they did this test. And they compared it to all the other SSRIs. Because, as you will learn, GSK never did this test. What Doctor Sloot discovered in May of this year is that out of all the teratogen --out of all the SSRIs, the 12, only one was a clear teratogen, Paxil. He discovered that Paxil in May of this year was actually more powerful a teratogen than cocaine. It would be safer, according to Doctor Sloot's study, to take cocaine than it would be to take Paxil while you were pregnant.
MR. TRACEY: I told you earlier that the way you learn about this case is through evidence, through witnesses that take the stand, through documents. And you are going to see documents in this case that have never seen the light of day before. You will see internal GlaxoSmithKline documents that the FDA hasn't seen, that the United States Congress hasn't seen, and that no jury has ever laid their eyes on before. For the first time in this trial you will see these documents. They have been under seal for over three years. And that's the way, one of the ways, you are going to learn about what GSK knew and when they knew it.
Tracey then explains to the jury how Glaxo had purchased the compound [paroxetine] from a Danish company called Ferrosan. He continues...
MR. TRACEY: Ferrosan had done the preliminary animal studies to look at teratogenicity. And they were done, I believe, in 1979 and 1980. And one of the studies was called Study 295. This is a study where they give Paxil, paroxetine, to pregnant female rats. And what the evidence showed in Study 295 is that the rats that got no Paxil, 88 percent of them were alive or 12 percent were dead by the fourth day after they were born. The ones that were given 5 milligrams of Paxil, 65 percent were dead by day 4. The ones that were dosed with 15 milligrams of Paxil, 92 percent were dead by day 4. And in the ones that were given 50 milligrams of Paxil, 100 percent were dead by the fourth day after they were born.
Ferrosan's Dr Baldwin
MR. TRACEY: At the time a doctor by the name of Baldwin, who works for them, Doctor Baldwin looked at the studies. He looked at Study 295, another study called 296, another study called 297. And 12 years before they started selling this drug to women in the world, Doctor Baldwin had some comments about these studies. What he told them internally -- this is a document that nobody has ever seen before. What he told them internally was: There remains the possibility this compound could be teratogenic at higher dose levels. As he saw, as you just did, that the more Paxil you got, the more rats died. And these were not heavy doses of Paxil. What he was concerned about was whether or not Ferrosan or anybody else was going to conduct or intended to conduct peri and postnatal studies to answer the question to why the rats died. He wanted to know that. In 1980 he sent a memo to the powers-to-be at Beecham. He said this needs to be done. The rats died. He talked about embryolethality. That means the fetuses die.
FDA Revolving Door
MR. TRACEY: Because I saw the animal studies that you just saw and the evidence that you will see about the animal studies and the rat pups dying, and I wondered how they could market the drug and say in the beginning that there were no problems with the drug. What I found out is that the FDA investigator that signed off and said you can sell your drug to the public is a guy named Gary Evanuic (sp.?). And Gary Evanuic, who signed off on Paxil being a Category B drug, now works for GSK. He works for GSK in the very department that sells Paxil.
MR. TRACEY: And as we are rocking along, in 1994 we are selling in the United States, we are selling in Europe. Business is brisk. Business is going well. And they want to move into other countries. They want to sell their drug in other countries. And they have a company called SmithKline or Smith Beecham Japan. It is one of their companies that is in Japan that sells their drug, one of their 70, I think, companies. And the Japanese, they suspected, were not going to accept their dead rat pup studies because they suspected the Japanese, because of the historical things that have gone on in Japan with birth defects related to Hiroshima, Nagasaki, and another environmental disaster there called Minamata, the Japanese had a heightened sense of concern. GSK believed that's what would be going on. And so GSK began discussions internally. Internally among themselves they said: What are we going to do, what are we going to do if Japan makes us do the studies to find out why the rat pups died? What are we going to do? Because what the documents, the internal documents that the FDA has never seen, that nobody else has ever seen, is, their conclusions were, if the Japanese make us do the studies to prove why the rat pups died, we might lose the United States market. So GSK was looking at science and research, not from the aspect of whether or not their drug was going to induce birth defects in children, but the evidence will be their only concern was commercial. Their only concern was whether they would lose the American market. The quote from them is: GSK concludes this is the study, the type of study we wish to avoid. We simply don't want to know the answer to these questions. They say: If the Japanese do request a study, if they do it, there is a potential problem, they may insist on us doing a study to their preferred design. And so what they did in March of 1994, they got a woman or man, I'm not sure which, I haven't been able to find out, named Gwyn Morgan. They got Gwyn Morgan involved. They put Gwyn Morgan in charge of reviewing the study designs that they would give to the Japanese. And Gwyn Morgan was to ensure for the company that any potential negative outcome from the studies is minimized. They designed the study to fail. They wanted the study to fail.
GSK Sales Reps
MR. TRACEY: GlaxoSmithKline has 110,000 employees. I think 40,000 of them are salespeople. What these people do, you will learn, is, they go to doctors' offices. And they take literature and they take cookies and they take lunch and they take pens and they take samples of Paxil. And they tell the doctors why they should prescribe their drug. These are bright, sophisticated, educated salespeople. They are the backbone of this company. And what they were telling doctors in the mid-1990s is that no drug is safer than ours for pregnant women.
Japan Revisited
MR. TRACEY: So we are rocking along. Remember that Japanese study I told you about, Doctor Patrick Wier? Well, they designed a study -- they avoided the studies they wanted to avoid and they designed a study that they thought would satisfy the Japanese, and they were right. But even in the study that was designed to fail, something cropped up, something that was potentially a problem for them. In this study done by GSK, which, quite frankly, by the way, was not a study designed to find out why the rat pups died, it was not a study designed to find out the answer to the questions Doctor Baldwin had in 1980, but some of rat pups did die, and they autopsied one of the rats. And in one of the rats they autopsied, they found that the rat that was found dead had edema, swelling around the heart, and it had a ventricular septal defect. The very same defect Lyam Kilker has. The very same defect that they had started receiving reports of in 1997. But they blew this off. They minimized it. In their conclusions they didn't even mention it. It is buried in the back of the study in an appendix.
Cannot Stop Taking Paxil
MR. TRACEY: Now, this case is primarily, primarily, about birth defects, primarily about what happened to Lyam Kilker and whether they knew about what would happen to him. But in the course of selling Paxil for the past 15 years other issues have come up. One of them is this. In the mid-1990s some studies came out, some literature came out, showing that Paxil had a significant problem with withdrawal. What that means is this. They were finding that women that took the drug and then want to the stop couldn't get off of it. So they would get sick. They would try to stop and they would get sick. And so they would be forced to keep taking the drug so they wouldn't be sick.
Glaxo Burying Data
MR. TRACEY: In the mid-1990s there had been some studies done, not by GSK but by others, and talking about withdrawal. This, you are going to learn from the evidence, caused them some concern. They were concerned about losing their market, losing their market to Prozac. And what they decided to do was, do their own study. And one of the documents you are going to see is this document, a document from a woman named Bonnie Rossello. Bonnie Rossello is the vice-president of GSK's marketing, Paxil marketing. And what Bonnie said in 1997 was: In response to this, let's do our own studies. Then we will own the data. If the results come back negative, we can bury it all. We can bury the evidence that our drug is a problem. In 1997 that's what she said.
The full opening statement can be downloaded HERE
After hearing evidence from both sides Jurors deliberated about seven hours over two days before finding Glaxo failed to properly warn doctors and pregnant users of Paxil's risk. The panel awarded $2.5 million in compensatory damages to the family of Lyam Kilker.
The GlaxoSmithKline company tagline is, "Do more. Feel better. Live longer."
Labels: Aropax, Birth defects, Ferrosan, Glaxo, GLAXOSMITHKLINE, gsk, King and Spalding, Paroxetine, Paxil, Sean Tracey, Seroxat
First do no harm... providing it's no longer than 8 minutes
Dr Bhamjee, caused controversy back in 2011 when he called on the Irish Government to add lithium salts to the public water
Dr. Moosajee Bhamjee, a soon to be retired psychiatrist from Ireland, showed exactly why the profession of psychiatry needs to take a long, hard look at itself when he was a guest on the George Hook radio show in Ireland on Thursday [11 April]
Hook had been contacted by Irish blogger, Leonie Fennell regarding a GP he had interviewed a week previously on his show.
The GP, Dr. Ciara Kelly, offered her opinion to a recent article that had appeared in the Irish press [Irish Examiner] that highlighted how GP's handed out antidepressant medication at the drop of a coin. An undercover journalism student, Niamh Drohan, had approached 7 GP's in Ireland and told them she was suffering from stress and anxiety problems from her final year in college. On each visit a prescription for an antidepressant was written for Drohan. Her article 'Depressing Truth about Treating Depression In The Young' can be viewed here. Fennell gives her take on it here.
Hook's interview with Ciara Kelly enraged Fennell so much that she emailed the show to set the record straight. Kelly had claimed , during the course of her interview with Hook, that "the drugs themselves are not dangerous, they're not addictive, they're not even dangerous at high levels of overdose."
Fennell's son, Shane, took 39 Cipramil in 17 days and his toxicology report showed a 'toxic to fatal' amount in his system. On the 17th day Shane, under the influence of the antidepressant citalopram, killed himself and another man. Podcast with Leonie Fennell here goes into more detail.
Fennell, along with antidepressant expert Prof. David Healy, were invited by Hook to offer their opinion as was Dr. Moosajee Bhamjee.
The interview [below] is interesting in as much that Bhamjee argues that in his 40 years as a healthcare professional he has never seen any patient who has experienced aggressiveness on these types of drugs. He also argues that Dr's only get an 8 minute slot to determine if someone is mentally ill and needs prescription medication. And there I was thinking that the Hippocratic oath taken by Dr's carried no disclaimers!
Bhamjee, caused controversy back in 2011 when he called on the Irish Government to add lithium salts to the public water supply in a bid to lower the suicide rate and depression among the general population.
Anyway... here's the debate from the Hook show.
If you are having trouble with the audio player then the audio can be downloaded direct to your computer by right clicking and 'save as' HERE
Leonie Fennell's blog
Labels: aggression, antidepressants, Dave Healy, Ireland, LEONIE FENNELL, Moosajee Bhamjee, Radio, Suicide
Alistair Benbow on Seroxat/Paxil Suicide
As a follow on from my last post, Alistair Benbow on Seroxat/Paxil Addiction, I now turn my attention to part two of the interview with Benbow, much of which never went to air on the BBC.
For those that don't know, Alistair Benbow was the spokesperson, nae mouthpiece, for GlaxoSmithKline any time an issue of Seroxat [Paxil] was raised in the media.
Here's Benbow being grilled by BBC's Shelley Jofre over Seroxat and the suicide link.
The transcript was downloaded via the Drug Industry Document Archive
Q = Jofre
A = Benbow
Transcript GSK Tape - Panorama Interview - Dr Alastair Benbow 9 October 2002
Q. Let us move on. What has the company done about the Wyoming verdict?
A. As I told you before, in this matter because of a confidentiality agreement between the family and GSK I am not able to specifically comment on the mitigation, but what I can say is that there is no reliable clinical evidence that Seroxat causes violence, aggression or homicide. This tragic, tragic case is something that does occur from time to time in patients who are depressed...
Q. This man had no history of suicidal thoughts or tendencies. The jurors sat and listened to all the evidence and decided that there were four deaths that were mainly caused by Seroxat. Your company was found guilty of negligence. You cannot ignore that.
A. No, and nor would we want to ignore it. This was a tragic case but we remain firmly convinced that Seroxat did not cause the tragic events in this case.
Q. So the jurors got it wrong!
A. No, I am not saying that. What I am saying - as I have said before - is that there is a confidentiality agreement between the family and GSK in this matter and I cannot comment on the specifics of this but we remain firmly convinced that Seroxat did not cause the tragic events in this case.
Q. It was pretty clear-cut. There was nothing else to explain his behaviour. He had only been on the drug two days and he clearly had a reaction that threw him into mental turmoil and made him behave in this way.
A. Yes, but there is a lot of speculation in the question you asked there but as I said I cannot comment specifically on this case because of a confidentiality agreement between the family and GSK. What I can say is that looking at all the data and the clinical trials there is no reliable evidence that Seroxat causes violence, aggression or homicide.
Q. All the evidence was produced in the trial. I am sure your company more or less produced the best evidence that was available. The jurors decided Seroxat was responsible for those four deaths and that is pretty serious.
A. As I have said before, I cannot comment on the specifics of the case...
Q. You cannot tell me that the clinical trials support Seroxat as not being linked to aggression or suicide?
A. Yes, I can say that. The clinical trial data and spontaneous adverse event data for reporting over the last ten years since Seroxat was made available in the UK do not support the finding that Seroxat causes aggression, violence or homicide.
Q. All of this data was presented to the jurors so they had ample opportunity to hear arguments on both sides and they felt Seroxat was responsible for the deaths.
A. As I say I cannot comment on the legal situation because of a confidentiality...
Q. I am not asking you to comment on the legal situation. I am asking you to comment on the fact that your company's drug was found responsible for four deaths.
A. As I said, I cannot comment on the specific situation but what I can say, quite clearly, is that when you look at the data from clinical trials and from the data in use in tens of millions of patients in 1999 that there is no reliable evidence that Seroxat causes violence, homicide or aggression.
Q. Is your company just going to ignore this verdict as if it never happened?
A. No we take very seriously any event that occurs when patients are taken off...
Q. What have you done to make sure that this does not happen again?
A. We have looked very, very carefully at the data, and as I say the data clearly shows that there is no reliable evidence that Seroxat causes violence, aggression or homicide.
Q. What does the warning in the patient leaflet mean then?
A. What do you mean?
Q. The warning about self-harm and suicide that is on the Seroxat leaflet, what does it mean?
A. As you will know, in patients who are depressed there is a significant risk of suicide and self-harm. That risk of suicide is at its worst when people have their worst depression, and that is often when people go to the doctor...
Q. Why would the risk of suicide increase once they start taking Seroxat?
A. No, I am not saying it increases when they start to take Seroxat; I am saying people are at risk of suicide early in treatment because it takes a while for an anti-depressant to work.
Q. The suggestion in the warning is that there is an increased risk in the first few weeks of being on Seroxat, but you say it is nothing to do with your drug?
A. What I am saying is that there is an increased risk of suicide early in the treatment of depression. Whatever the treatment, or indeed if there is no treatment there is an increased risk of suicide, and this is a very...
Q. So it is just a co-incidence that the increased risk of suicide starts when they start taking Seroxat?
A. No, what I am saying is that there is an increased risk of suicide even if patients receive no therapy. This is a fact of people who have depression. The reality is that many people with a severe depression have a very low mood and loss of energy. As people start to recover their energy and mood encourages...
Q. But they are not recovering, you say, until a few weeks after they start the Seroxat.
A. Early on in treatment the major affects of anti-depressants take a week or two to start, but the reality is that energy levels are one of the first things that start to improve, but mood comes later.
Q. Is it not that they get agitated?
A. Not at all. Not at all.
Q. It sounds to me here as though you are trying to have it both ways. You are trying to say the risk increases when you start taking the drug but it is nothing to do with the drug. It is meaningless warning.
A. No the warning is there, and has been agreed with the regulatory authorities, and it is basically to tell doctors, 'Look, you have a patient who is depressed. They are at risk of suicide. Don't just think just because you have started them on anti-depressants that they are not going to remain at risk of suicide immediately. The fact is that antidepressants take a while to work. If you look at the data what does the data show? The data shows that Seroxat reduces suicidal ?hydration and thought. Over the past ten years - or the ten years between 1990 and 2000 - with the increasing use of antidepressants, suicide rates in England and Wales have fallen by 15%...
Q. Are you taking credit for that?
A. I am saying that the increased used of anti-depressants, the better diagnosis of depression and the better treatment that is available - yes, that has contributed to the fall in suicide rates.
Q. Perhaps over the long term drugs like Seroxat are useful for avoiding suicide and reducing suicide rates but what we are talking about is a window in the first few weeks where there is quite a lot of evidence that people can become agitated, restless and anxious. It seems to correspond exactly with the period that you are saying there might be an increased risk of suicide but you are saying it is nothing to do with your drug.
A. No, I must disagree with the comments you made. There is not a lot of evidence to suggest that patients are getting agitated and restless and anxious. The reality is that anti-depressants do take a short while to work, and during that first few weeks, when patients are taking therapy, doctors should be aware that patients are at risk of suicide, because of their underlying depression.
Q. So it is not an increased risk. I do not understand what you are saying. If you are saying, 'Until the anti-depressant starts working they are at the same risk of suicide as they have always been' then that is one thing. However, your warning says there is an increased risk of suicide...
A. What I am saying is the greatest risk to patients of committing suicide is in those who are severely depressed.
Q. But in those first few weeks of... [talking simultaneously] start Seroxat?
A. No, the most severely depressed patients are those that have just presented their doctor and just started on therapy.
Q. Of course not everyone take Seroxat for depression and we have spoken to someone who took Seroxat for panic attacks and he began to self-harm in the first few weeks of taking it, something he had never even dreamed of doing before.
A. Seroxat is indeed available for a range of depression and anxiety related disorders, all have clear criteria for laying down exactly what the conditions are. There is a range of different conditions - panic disorder, obsessive-compulsive disorder, social anxiety disorder etc. Many of them are associated with depression and the same patients will be at risk of suicide and...
Q. Again is it just a coincidence this behaviour would start a few weeks after taking Seroxat?
A. No I am not saying it is a coincidence. I am saying it is a reality of depression and other related disorders...
Q. Panic attacks?
A. Yes, panic attacks and...
Q. I thought that is a link to self-harm.
A. Panic attacks are linked to depression, which is linked to self-harm.
**At this point Jofre pushes home the point about Seroxat withdrawal - She then continues with...
Q. Well, let us move on. Here is a drug that is linked to suicide and self-harm, a drug that thousands of people say they are addicted to; do you seriously think it should be given to children?
A. Let me just correct something in your question. There are a number of allegations you made there none of which are correct. In terms of whether we think Seroxat should be made available to children, absolutely. Two percent of children, 4% of adolescents, will develop depression. The adolescents are at particular risk of suicide.
Q. You think this is safe for children?
A. I think we need to do the trials to determine this. We have an obligation to make our medicines available to those patients at need. Adolescents are some of the patients who are most at need of anti-depressants. Suicide in adolescents is the third leading cause of death. Do not trivialise depression for those patients. We have a strong obligation to study our medicine in these patients to see if we can help them.
Q. In a recent study that Glaxo funded more than 10% of children developed psychiatric problems within eight weeks of taking Seroxat.
A. I think you will have to tell me a little more about the specific study so that I can understand your question.
Q. It was funded by Glaxo and carried out in America - the biggest ever study of Paxil in depressed children and more than 10% of children developed psychiatric problems within a few weeks of taking Seroxat.
A. I think in any study a proportion of patients (as in this particular study) where patients were either taking Seroxat, or Imipramine, or a placebo, a proportion of patients will develop adverse effects in the course of the study.
Q. There were far more children on Seroxat than on the other drug, or on sugar pills who developed these psychiatric problems.
A. There are a number of different elements that you lump together in psychiatric disorders.
Q. I will run through the list of problems if you like. Five of the children suffered suicidal thoughts and gestures. There was aggressiveness. There were behavioural problems at school. None of this sounds very safe; it all sounds quite worrying for the children who are on Seroxat.
A. Actually not because some of those symptoms were also seen on the patients taking Imipramine and placebos.
Q. Not as frequently.
A. Maybe not as frequently, but they still suffered. This is typical of the sort of symptoms that occur in this population of patients. This is a difficult population to treat and you will be aware that for many medicines there is no licensed implication for use in children so much of prescribing in children is done off-label. We firmly believe that we have an obligation to study our medicine to treat population to examine the safety and the efficacy of that medicine.
Q. I appreciate that but there were many problems on Seroxat than on the other drug or the sugar pills.
A. Actually the majority of those side effects were relatively minor.
Q. No, a lot of these children were hospitalised it was so serious.
A. If you look at the proportion of patients who withdrew from therapy - and you can see less than 10% had to withdraw from Seroxat - more than 30% withdrew from the other active therapy and just under 10% withdrew from the dummy.
Q. It is heart complaints with the other drug, and I understand that, but-
A. But that is the sort of therapy that is the alternative, which is why it is very important that we study Seroxat in this group of children who are most at risk from suicide.
Q. What we are talking about here though are psychiatric side effects, the sorts of side effects that can lead to suicide and there were far more children on Seroxat suffering these problems than on the other drug or sugar pills.
A. What you are trying to do is make a link here with the adult data. The adult data clearly shows that there is no reliable scientific evidence that Seroxat causes suicide.
Q. But why should it be that so many more children should suffer these side effects on Seroxat than the other drug or sugar pills.
A. Actually, if you look at the more serious of those side effects the number difference was very small, and the sort that you would expect to see in clinical trials. On one trial there may be more than on another, in another it will go the other way.
Q. And for the 10% of the children on Seroxat who had these side effects you are not worried that it was caused by the drug?
A. The vast majority of these patients did not have side effects significantly enough to withdraw from the treatment. The reality is that in this population depression is an extremely serious condition and in many cases leads to suicide.
Q. I appreciate that.
A. Are we worried by the side effect profile? We take the safety of our medicines extremely seriously and we will look very carefully at this, and the combination of other data, to decide whether this medicine is suitable for children. My belief is that it will be but because there is a lack of treatment for this serious condition that this medicine will be suitable for a range of children as well as adults.
Q. You cannot be sure that the 10% of children on Seroxat who suffered these problems did not suffer them because of Seroxat can you? You cannot be sure about that.
A. One can never be sure of anything in medicine, but just because you take a medicine and you get an effect does not mean to say cause and effect because the same sort of symptoms occur with the dummy pills.
Q. That is why if you compare it to another drug and the sugar pills, in that comparison Seroxat was much worse.
A. In that comparison the proportion of patients withdrawing from the study due to adverse events was much lower on Seroxat than one of the other potential treatments available.
Q. There are 60 psychiatric side effects - the sorts of side effects that are linked with suicide and self-harm.
A. Let us look at the totality of the adverse event profile because it is the total risk and input that is important.
Q. We are considering the link with suicide, and this evidence points very strongly to the fact that more children are suicidal and had suicidal gestures in fact on Seroxat than the other drug.
A. With respect the totality of the data is important. What you are talking about are five patients out of the 275 on Seroxat, three patients on Imipramine. That difference is not significant and one patient had a placebo.
Q. No, I am talking about five children. The figures are-
A. I have given you the figures. Five on Seroxat, three on Imipramine and one on placebo.
Q. There were children out of 93 children on Seroxat who had suicidal thoughts and gestures, another five out that 93 had serious psychiatric side effects. Do you not think parents would be worried about that if their child were to be given this drug?
A. I believe that what parents would be more worried about is the risk that their children had of committing suicide and other symptoms of severe depression if no treatment was available. In my opinion parents want treatments to be properly evaluated during clinical trials before their children are given any medicine.
Q. But the evidence here suggests that their children might be at more risk of suicide if they go on Seroxat.
A. No, the evidence is not there. There is no statistical difference between the groups. The reality of the situation is that in this trial Seroxat was generally well tolerated by this difficult to treat population.
Q. You are not concerned about this and you do not think parents should be concerned about this?
A. What I am saying is that we are attempting to study Seroxat in this difficult to treat population. If, and when, we demonstrate the efficacy and the safety of the product, then the data will be submitted to the regulatory authorities with a view to getting a licence so that these patients and their doctors have another treatment available to them to treat this difficult disease.
Q. You would like it to be licensed for children?
A. Of course it must be driven by the data. There are many times we do clinical trials where you find that the balance of risk and benefit is not capable, in which case you do not try and get a license. The reality in this situation is the data we have generated so far is favourable. There is more benefit than risk in this population but until we have developed all the clinical trials, and done a full package of information, and adequately studied this drug in this population we cannot say that.
Q. Are you satisfied then that your company, generally, has done everything it can to keep patients properly informed about the negative side of the drug?
A. Absolutely, and it is not something we just sit and watch. Our summary of product characteristics is a living document. You start with a very limited number of healthy volunteers. Then you develop the clinical trials in thousands of patients. Then you make it available to tens of millions of patients around the world. As time moves on you collect more information and more data becomes available, and as a result we regularly change the information, which we provide to prescribers and patients for all our medicines, and of course for Seroxat as well. We will continue to do that. We will continue to monitor the safety of our medicines. We will make changes to the information to prescribers and patients, driven by facts and data not by anecdote.
Interview ends.
Less than one year after this interview a review of Seroxat data by the Committee on Safety of Medicines (CSM) showed that children taking tSeroxat may be more likely to self-harm or partake in suicidal behaviour. The Medicines and Healthcare products Regulatory Agency (MHRA) has also warned that adults who are on the drug should not suddenly stop taking it.
The review found that studies on more than 1,000 children also suggested those on Seroxat were at least twice as likely to have suicidal thoughts or self-harm compared to children with similar mental health problems who are not taking the drug.
Ironically, they only found this evidence after GlaxoSmithKline had sent in data because they wanted the MHRA to grant a licence for Seroxat to be used in children.
It was estimated that between the period of Alistair Benbow's interview with Shelley Jofre and the release of the news that Seroxat could cause suicide in kids, 8,000 patients under the age of 18 were treated with Seroxat in the UK.
In 2007, the BBC aired its fourth Panorama documentary regarding Seroxat.
On Monday January 29, 2007 Panorama showed shocking footage that demonstrated how GlaxoSmithKline's Public Relations people and marketing department 'spun' negative trial results on children which showed serious risk of suicide, self-harm and aggression.The trial also indicated Seroxat was no more effective than a sugar pill.
GlaxoSmithKline claimed to doctors that the drug was 'remarkably' safe and effective for under-18s, with the support of an 'independent' professor of psychiatry [Martin Keller] who earned $500,000 in fees from drug companies in one year.
Seven out of the 93 children in the Seroxat group had to be hospitalised for adverse reactions ranging from self-harm, aggression, violence to others and suicidality (suicidal thoughts or actions, meaning actual suicide attempts)
In other words, almost 8% of children in the Seroxat group had the above adverse reactions.
What was it Benbow said in the interview?
"There is no statistical difference between the groups. The reality of the situation is that in this trial Seroxat was generally well tolerated by this difficult to treat population."
Was Benbow lying or was he not aware that data showed this significant [8%] figure?
In an internal company memo dated 14 October 1998, four years prior to Benbow's denial, GlaxoSmithKline executives concluded that Seroxat did not work and that a licence application would be refused: 'The results of the study were disappointing. The possibility of obtaining a safety statement was considered, but rejected.' The best they felt they could achieve was a statement that 'although safety data was reassuring, efficacy had not been demonstrated'.
Did they go public with this?
The self-harm, aggression and suicide attempts were kept quiet as was the lack of efficacy of Seroxat in children. PR people took over to implement a new plan: promote Seroxat to doctors as a treatment for under18's.
GSK's plan was simple and, it has to be said, unethical. They tried to persuade doctors that Seroxat was suitable for their child patients. From the 1998 internal memo showing that efficacy had not been demonstrated they spun the whole trial on its head with the clear message that Seroxat was 'remarkably effective and safe for children'.
KOL's - key opinion leaders in the field of child and adolescent psychiatry.
Martin Keller was, at the time, a renowned expert in the field of child and adolescent psychiatry. If Glaxo could get Keller to endorse the use of Seroxat in children then they were on to a winner.
Enter the ghostwriting machine.
Glaxo hired a PR firm to draft an article claiming Seroxat was beneficial for children. Keller put his name to the article which was later published in widely read journals. Job done, suicidal attempts, aggression and self harm were all hidden.
GlaxoSmithKline simply buried the data, including data from another, later trial on children which found that the placebos given to the control group of depressed kids 'worked' better than Seroxat!
Glaxo later, forced by US medicines regulator the FDA to re-evaluate the raw data from Study 329, admitted to four further adverse reactions in which children became suicidal, raising the number suffering severe reactions to the drug from seven to 11 — a shocking 12 per cent of the total, and representing a 600% increase in events related to suicide.
Benbow knew nothing... apparently.
This half hour documentary goes into more detail about the whole sordid affair.
Labels: Addiction, ALISTAIR BENBOW, Aropax, Dependency, Discontinuation, Glaxo, GLAXOSMITHKLINE, gsk, Lawsuit, Litigation, MHRA, Paroxetine, Paxil, Seroxat, Suicide, withdrawal
Former GSK Head of Psychiatry Alastair Benbow
The following is taken from a BBC transcript, much of which never went to air.
It's an interview with GlaxoSmithKline's, then Head of Clinical Psychiatry, Alistair Benbow.
Benbow, you remember, was the spokesperson who defended Seroxat... and even suggested that it may, at some point in time, be used on kids. He's not a fan of mine either, in 2008 I, apparently, caused him unwarranted distress with a video I created [see - Glaxo, An Angry Blogger And Free Speech]
The following segment was taken from a 2002 interview undertaken by BBC journalist, Shelley Jofre and focuses on Benbow's reaction when asked whether or not Seroxat [Paxil in the US] is addictive. It's a marvelous defence of a not so marvelous antidepressant.
Q. Your leaflet says 'remember you cannot become addicted to Seroxat', but that's not true is it?
A. Yes, it is true. There is no reliable evidence that Seroxat can cause addiction or dependence, and this has been borne out by a number of independent clinical experts, by regulatory authorities around the world, the Royal College of Psychiatrists, and a number of other groups.
Q. If people cannot stop taking a drug when they want to stop taking it they are addicted are they not?
A. No, that is not correct. The definition of addiction is not as you describe it. Addiction is characterised by a number of different criteria, which includes craving, which includes increasing the dose of the drug to get the same effect, and a number of other features, and those are not exhibited by Seroxat.
Q. That is not with respect what the Oxford English Dictionary says. It says, "Addiction is having a compulsion to take a drug, the stopping of which produces withdrawal symptoms."
A. It is true that a number of patients will experience symptoms on withdrawal.
Q. That is what addiction means is it not?
A. No, it is not.
Q. That is what the dictionary says.
A. That is not a clinical definition of addiction or dependence. Dependence is very clearly laid down by international...
Q. But when people start taking Seroxat they do not consult a medical dictionary.
A. No, and they will not consult the Oxford English Dictionary either.
Q. The Oxford English Dictionary tells you what common usage of the word addiction is. People understand that if they cannot stop taking a drug it is addictive.
A. The reality of the situation is that regulatory authorities around the world, independent clinical experts and key groups like the Royal College of Psychiatrists, have agreed that Seroxat is not habit forming or addictive.
Q. But your patient leaflet is meant to help and inform patients is it not?
A. Yes, it is, and it does I believe.
Q. Not according to the people we have spoken to who feel they were not warned that this could happen to them. They read, "You cannot become addicted to Seroxat" and thought they could stop the drug any time they wanted.
A. No, the reality is they can stop the drug, but it is true...
Q. But you cannot stop any time you want.
A. Yes, they can and the information clearly says that Seroxat is not addictive, and it is not. It is true that a proportion of patients may develop symptoms on stopping the drug. These are generally mild to moderate in nature ... [Inaudible due to interruption] permitting, and will go away usually within a two-week period.
Q. I am sorry, I must take you back to this because the dictionary says, "having a compulsion to take a drug, the stopping of which produces withdrawal symptoms", and we have spoken to plenty of people who say they are compelled to take Seroxat because stopping it produces withdrawal symptoms. They are addicted.
A. If you use that limited description of addictive then most prescription medicines could be defined as addictive. Beta-blockers, which are used for the treatment...
Q. This is the common usage of the word. This is what people understand "addicted" to mean, and you are misleading them in the patient leaflet by saying they cannot become addicted.
A. No we are not misleading them. The information in the patient leaflet, and in the information supplied to doctors, is based on fact. It is based on data, which is generated during clinical trials and during the marketing of the product over the last ten years.
Q. Do patients' experiences count for anything in this?
A. Of course patient experiences count for something, and we take the safety of our medicine extremely seriously, and we take into account all the adverse events that are recorded throughout the world and report them to the regulatory authorities. It is on that data on which decisions are made as to what should and should not be in our leaflet and in the information to doctors. The regulatory authorities are very, very clear on this issue. There is no reliable scientific evidence that Seroxat causes addiction or dependence.
Q. It sounds to me that you are hiding behind the medical definition of addiction. The World Heath Organisation says that proper dependence is "a need for repeated doses of a drug to feel good or avoid feeling bad". We have spoken to countless people who are on Seroxat and the only reason they are still on it is because they cannot stop taking it - they feel too bad when they stop taking it.
A. As a doctor it is my duty to inform patients on the risks and the benefits of our medicines. It is important...
Q. You say it is doctor's responsibility, not yours?
A. No, I am saying as a doctor myself it is my responsibility for my patients to inform them of the risks and benefits of an individual product. Now we help doctors supply information...
Q. But this is not helpful! What I am telling you is that we have spoken to countless people who feel that they have been misled by the patient leaflet. It says you cannot become addicted to Seroxat, and by any definition that the public might look at they are addicted.
A. No, I am sorry I have to disagree with you. When you look at the data it quite clearly shows that on all the models when you do trials in animals - when you look at the data in patients considering taking this in the context of tens of millions of patients who have been on Seroxat over the last ten years - the data clearly shows that this class of drugs, and Seroxat in particular, does not cause addiction or dependence.
Q. It does not cause addiction if you use the medical definition perhaps, but what we are talking about here is information that helps people to make an informed choice when they go on a drug, and that leaflet is misleading them because they think they can stop the drug any time they want. They cannot can they?
A. Yes, they can.
Q. But they cannot. It is quite obvious that there are large numbers of people who cannot stop taking the drug because the withdrawal symptoms are causing them too much distress.
A. With respect, patients can stop taking Seroxat. Of course they should be taking it in consultation with their doctor...
Q. There are some people for whom the withdrawal symptoms are really quite terrible.
A. I understand that, and I have every sympathy with patients who are having difficulty...
Q. So you accept that some people will have a very difficult time coming off the drug, but they would not know that from reading your warning.
A. There is a very small percentage of patients who will experience difficulty coming off Seroxat and a range of other therapies.
Q. But they would not know that, would they, when they are on it?
A. It would be absolutely scandalous if we were to put in our patient information, information that was not correct and we are not going to do that.
Q. But you are misleading people because if you say you cannot become addicted to Seroxat it makes people think it is a benign drug that you can stop taking any time you like.
A. No, that is not correct. We are not misleading the public at all. We are providing factual information that is correct.
Q. If you look at the patient leaflet it also says "withdrawal symptoms from Seroxat are not common". That is not true either, is it?
A. Yes it is true. That information is absolutely accurate. Withdrawal symptoms are not common.
Q. Doctors report far more withdrawal problems with Seroxat than with any of the other anti-depressants.
A. If you are referring to list withdrawal symptoms then in the context of tens of millions of patients who have received Seroxat around the world the numbers of withdrawal symptoms are actually very low.
Q. But you agree Seroxat is far and away the worst offender for withdrawal problems.
A. What I am saying is that in those lists the absolute number of reports, which are relatively low in the context of the tens of millions of patients who have received Seroxat, it is at the top of the list.
Q. The side effects are always notoriously under-reported by doctors. The fact is that Seroxat tops every single list there is of withdrawal problems.
A. The reality is that when you tell people about these side effects, as we have done - we have warned them in the patient information leaflet and we have told doctors about symptoms on withdrawal - it is more likely they are reported. However there are many other confounding factors.
Q. Excuse me if I do a little basic arithmetic here. Seroxat is prescribed slightly less than Prozac, and yet the complaints about Seroxat withdrawal problems are far and away the highest out of any anti-depressant.
A. Let me just tell you a little bit of technical information...
Q. That is true is it not!
A. It is true that in those particular lists Seroxat does feature at the top of the lists.
Q. And why is that?
A. For reasons that I have already outlined you have to take on board a number of different factors, one of which is the frequency of prescribing of the drug. However there are other factors, like the amount of drug that is in the blood over time, so the half-life of the drug ie. how quickly the drug is washed out of the system is also important. With Prozac, for instance, the half-life of the drug is very long so there is therefore a long time between stopping the drug and experiencing symptoms, so long in fact that many people may not recognise that the symptoms they get on stopping are related to the drug. Whereas, of course, when you have a short half-life - and for a product to wash out of the system quickly is a very beneficial thing - then they are more likely to recognise it.
However these symptoms on withdrawal are common to all anti-depressants, not just the SSRI's and is common to many, many other drugs, including treatment for high blood pressure, cardio-arrhythmias and so on.
Q. It sounds like you are trying to say that Seroxat is no different to the other antidepressants, but whatever evidence you can count that is simply not true. Talking to patients, talking to doctors, and looking at any list that complies lists of withdrawal problems, Seroxat is much worse than the other anti-depressants.
A. What I am saying is that you cannot compare absolute numbers...
Q. You must accept that surely?
A. No, I do not accept that. It is my fundamental belief that Seroxat and the other antidepressants of all classes cause symptoms on withdrawal.
Q. There is no difference between Seroxat and the other anti-depressants?
A. There may be a difference in the number that are reported on occasion because we-
Q. Because there are more problems?
A. Because we have highlighted the fact these sort of symptoms have become more apparent since Seroxat was made available, and there are many other factors which need to be taken into consideration as the regulatory authorities will tell you.
Q. Have you looked on the internet, or spoken to patients about this?
A. Yes, I have and actually the majority of patients do not have a problem.
Q. Tell me about the patients who do have a problem because their problems are very real indeed. Your leaflet says 'withdrawal symptoms will generally disappear with a few days'. Have you looked on the internet and seen some of the horror stories?
A. Yes, I have looked on the internet but I have to tell you that the majority of patients who experience withdrawal symptoms - and the majority of patients actually do not experience any withdrawal symptoms - of those that do the majority of those symptoms are mild to moderate in nature and will go away without any treatment within two weeks.
Q. You say you have looked at the internet and spoken to patients, but why have you not heard the stories we have heard of people who are having a terrible time? Sometimes they cannot get off it, other times it takes them a very long time indeed and lots of unpleasant withdrawal symptoms.
A. Of course I have read those same stories. Most of those...
Q. So, they are true are they not?
A. Most of those I have seen in the media and we cannot be driven by anecdote; we have to be driven by facts. We do not...
Q. So you do not listen to patients?
A. Of course we listen to patients. We listen to patients all the time, but the reality is that we have to consider the facts and we will collect data and we do, and the regulatory...
Q. These are facts!
A. And the regulatory authorities collect the facts and data, and then they make a decision as to whether these things should be changed in our label.
Q. Are you saying that these patients' stories are not fact? Do you think they are making it up?
A. No of course I am not saying that. What I am saying is that if you look at the totality of the data - and yes it maybe that a small proportion of patients do get more severe symptoms but in totality of the total patients taking Seroxat, an extremely effective and valuable medicine for the treatment of this severe disease, depression, which kills many people...
Q. It is not just for depression that people are taking the drug.
A. Indeed not - for depression and other anxiety related disorders, all of which have a common feature of being debilitating and stopping people functioning properly.
However, in that context I believe, the company believes, the regulatory authorities believe, and the independent clinical experts believe that the majority of these symptoms on withdrawal are mild to moderate in nature, self-limiting and go-away in the majority of cases within two weeks. Now these symptoms can also be helped if you gradual taper the medicine on withdrawal and that information is in the information that is provided to doctors and to patients.
Q. How long should it take then if you taper the withdrawal?
A. That depends on the dose of Seroxat that the patient is on. In the majority of cases, if you are on one of the higher doses, it will only take a matter of weeks.
Q. We have been filming with a woman - she has actually filmed her own attempts coming off Seroxat - and it has taken her nine months and it has been absolutely horrendous! She has been unable to leave the house on a large number of occasions as the symptoms have been so bad.
A. With respect you are taking, yes I grant an extreme example, which is very disabling...
Q. It hardly an extreme example if you look on the internet!
A. If you will forgive me for saying so, it is an extreme example because although there may be a whole range of anecdotes on the internet, there are also many, many millions of patients who have taken Seroxat for this disabling and stressing condition...
Q. Nobody is denying that a great many people have been helped by this drug. What we are talking about is the information you provide for patients and whether it is accurate. If somebody goes on a drug and they are told they cannot become addicted, withdrawal symptoms are not common and they are generally going to disappear within a few days, you would forgive them for being a little angry when nine months after trying to stop they are still on the drug!
A. I think you will find that the information you just said that is in the patient information leaflet in the summary of product characteristics is accurate, balanced and not misleading.
Q. What warning would there be for anyone who goes through this horrendous withdrawal process?
A. No, what we have said...
Q. There is definitely no warning that they might experience this is there?
A. It is important to understand that what we are trying to do is label for the usual situation. Of course, in medicine and in...
Q. The woman I am talking about took this drug for panic attacks. If she had known at the time that she was going to go through this horrible withdrawal from the drug, she would never have taken it. She would have managed her panic attacks in a different way. She was not properly informed and she is pretty angry.
A. This is an extreme example...
Q. It is not an extreme example.
A. It is an extreme example. The vast majority of patients, as we quite clearly say in our label, have no problem coming off Seroxat. Indeed...
Q. So it is just your tough luck if you happen to have a hard time?
A. No, of course not. I have every sympathy for any patient that has difficulty coming off Seroxat but that is not what normally happens. The vast majority of patients who take Seroxat will not experience any difficulties coming off it.
Q. The fact is that you do not know what normally happens because you do not have a published study that has actually looked in into the single question of addiction and withdrawal problems have you?
A. We have actually looked very carefully at...
Q. No, you have not conducted a study looking into withdrawal problems have you?
A. Yes, actually in all of our clinical studies we have looked to see where there are symptoms...
Q. No, a study designed to look at withdrawal symptoms.
A. We have specifically in all our recent studies looked carefully to see the proportion of
patients who get withdrawal symptoms.
Q. I am afraid you are not really answering the question.
A. Yes, I am.
Q. You have not done a study - a single study - looking purely at withdrawal symptoms have you?
A. What we have done is conducted clinical trials...
Q. Can I take that as a "no"?
A. No, you cannot take that as a "no". What you are saying is incorrect. To study withdrawal symptoms you have to have patients on Seroxat who you then follow during the withdrawal phase. That is exactly what we have done across a range of different indications, and quite clearly that information from those clinical studies
completely supports what we have in our leaflet.
Q. Can you show me the study that was designed to look at withdrawal problems?
A. I can show you a range of different studies that are designed to look at withdrawal symptoms and I can tell you the findings of those studies. In those studies approximately 7% of patients experience dizziness, 2% of patients experience abnormal dreams and 2% experience sensory disturbances. All the other adverse events that were seen on the form were at a lower frequency than that, and it should be remembered that patients who came off placebo also experienced withdrawal symptoms in some cases.
Q. You are not suggesting Seroxat's withdrawal problems are the same as sugar pills are you?
A. No, I am not, but what I am saying is that in interpreting data you have to take on board the consideration of a proportion of patients who take dummy pills who will also experience symptoms.
The interview then moves to the subject of Seroxat induced suicide.
One has to ask here if Glaxo's spokesperson was being honest. A year previously, in 2001, a lawsuit was filed in the US which claimed that Seroxat caused severe withdrawal problems.
The lawsuit showed that GSK deliberately misled both physicians and patients into believing that Seroxat was not addictive and had no or only rare withdrawal reactions with a question and answer pamphlet distributed to doctors' offices to be disseminated to patients, in which GSK asks the question: "Is Seroxat addictive?"
And, in response, the pamphlet states: "Seroxat has been studied both in short-and-long-term use and is not associated with dependence or addiction."
By the time the lawsuit was filed on August 21, 2001, the plaintiffs' attorneys, Baum Hedlund law firm, had been individually contacted by approximately 5,000 Seroxat withdrawal victims.
As a result of GSK's fraudulent marketing of Seroxat Baum Hedlund law firm won a major settlement in this class action filed on behalf of patients who got hooked on the drug, and in many instances, found they were unable to stop taking it. Sadly, because of the settlement, depositions and other important documents were sealed away from the public.
The documents that did surface during litigation showed that before Seroxat was approved, GSK had known about the withdrawal effects from it own clinical trials.
According to the lawsuit's complaint, "GSK's motive of deliberately failing to advise physicians and the public of the adverse effects that can lead to withdrawal problems (and that it knew a percentage of users of the drug inevitably would experience) was for financial gain and its fear that, if properly labeled the drug, Seroxat would lose its share of the SSRI market."
The now infamous 'money bag' memo also appeared during litigation [fig 1]. This showed clearly why Glaxo wanted to play down the dependency issue - something that Benbow, it seems, did a year later on BBC television.
In fact, in 1997, some 5 years before Benbow's interview with Jofre, GlaxoSmithKline had sent a memo out to its 'Paxil selling team'.
The memo, from Bill Kinnear and Barry Brand, refers to 'discontinuation syndrome' [withdrawal] and they blame Eli Lilly for mudslinging about Seroxat withdrawal due to the fact that Lilly's Prozac had come under scrutiny for causing severe adverse withdrawal reactions.
Kinnear and Brand instructed the sales team [Glaxo reps] with the following: [fig 2]
fig 2 - click to enlarge
It seemed to be one big joke for Glaxo, as the cartoon image of a patient screaming for his Paxil taken from the same document shows [fig 3]
GlaxoSmithKline, although settling 5,000 withdrawal cases in the US, still refuse to admit that Seroxat is addictive, still refuse to answer patient questions regarding how one should safely taper from Seroxat, still refuse to meet with patient representatives [ See - GSK's Andrew Witty in Patient Aftercare Snub], still defend their corner, the UK Seroxat lawsuit has never been settled, GSK contest that Seroxat causes withdrawal problems to patients in the UK, a case that has been on-going for approx 7 years.
In fact, Benbow throughout the above interview, refuses to budge on his [Glaxo's] addiction stance, strange then that in the same year as he was interviewed lawyers in America sought a preliminary injunction on behalf of thousands of Seroxat class members as well as individuals who, it was argued, "might be persuaded by the commercials and brochures to take Paxil in the future." Once again it was Baum Hedlund who put a stop to GlaxoSmithKline's TV advertisement claiming that Seroxat was "Non Habit-Forming". [See Paxil Ad Injunction]
More about the UK lawsuit with the 4 links provided at the end of this post, you'll note the MHRA's involvement with the UK Seroxat litigation, a former employee of the MHRA is an 'expert' witness for GSK. You'll also note from the above Benbow interview that he refers to the MHRA as the 'regulator'.
So, is Seroxat addictive?
My answer to that is in my book, The evidence, however, is clear...the Seroxat scandal.
As for Benbow, he no longer works for GlaxoSmithKline, he is now Executive Director of the European Brain Council [EBC]
Coming next: Alistair Benbow on Seroxat/Paxil suicide.
UK Seroxat Lawsuit Links
GlaxoSmithKline/MHRA - When Ignorance Turns To Bliss - Part I of IV
GlaxoSmithKline/MHRA - When Ignorance Turns To Bliss - Part II of IV - Witness For The Defence
GlaxoSmithKline/MHRA - When Ignorance Turns To Bliss - Part III of IV - Expert Statistician
GlaxoSmithKline/MHRA - When Ignorance Turns To Bliss - Part IV - The Colour of Money
Labels: Addiction, ALISTAIR BENBOW, Aropax, Dependency, Discontinuation, Glaxo, GLAXOSMITHKLINE, gsk, Lawsuit, Litigation, MHRA, Paroxetine, Paxil, Seroxat, withdrawal
Jenson Button - Gullibility in a Bottle?
It kinda sickens me when I see highly paid sports personalities, actors, pop/rock legends promote the use of pharmaceutical wares - be they prescription medications or consumer products.
I understand that careers are short in the above industries, unless you acting capabilities of the De Niro, Pacino ilk.
Jenson Button is a young man, idolized by many. He performs miracles as he travels at huge speeds in his race car - He has a huge fan base and it's probably hard for him to decipher who his real friends are opposed to the hangers-on who, when the chips are down, will leave him by the wayside and move on to the next hero.
I have no personal interest in Jenson Button, McLaren or Motorsports - in fact, I find Motorsports mind-numbingly boring, to me it's akin to watching a goldfish swim in circles... only far more noisy.
For those that don't know... and I only know because I've sat and researched, Jenson Button is a British Formula One driver from England currently signed to McLaren. His interest in driving fueled by his love for Karting from the age of just 8 years of age.
I'm not about to write a biography on Button, if you want to know more use Google as a resource.
I am, however, interested in Button's recent alignment to British pharmaceutical giant, GlaxoSmithKline. Sure, it's purely about the money - sponsorship deals usually are, only in this instance Button, I truly believe, has been misguided by his people, the very same people that will leave him by the wayside when a better child protegee comes along.
Button is currently promoting GlaxoSmithKline's Lucozade Sports, a drink that has been the subject of controversy during the past few years or so. This really isn't my issue with Button's gullibility, naivety, ignorance... call it what you will.
The one striking fact is that Button is promoting GlaxoSmithKline, a pharmaceutical company that have a very dark history when it comes to the safety and efficacy of medicines in children and adolescents.
Button, ironically, seen here with a whiskey promotion on his helmet [Fig 1], it would appear is all about the money - and why shouldn't he be, his career will be short.
There are other ways of earning money through sponsorship and to align oneself with a pharmaceutical company with an appaling record of disregard toward children may be something Button's advisers either overlooked or were blinded by the sign of the $$$.
This, is for Button, it's for his advisory team, it's for McLaren.
I doubt for one minute that Button or his highly paid PR team will flinch at the following. I can't imagine that they went into this sponsorship deal without knowing what they were advertising and who the manufacturers were... more importantly, the history of the manufacturers behind Lucozade Sports drinks.
Would Button have agreed to the sponsorship deal if he knew that...
The Rohm & Haas Company and SmithKline Beecham P.L.C. agreed to spend about $125 million to clean up the former Whitmoyer Laboratories site in Myerstown, Pa., the Justice Department said. Whitmoyer Laboratories manufactured veterinary pharmaceuticals from 1934 to 1984. During that time, toxic materials -- aniline and soluble arsenic compounds -- were produced, stored and disposed at the site. [1]
A Wyoming jury awarded $6.4 million to the family of a man who killed three relatives and himself after taking the antidepressant Paxil, manufactured by GlaxoSmithKline [2]
British drug regulators warn that GlaxoSmithKline's popular antidepressant Paxil causes depressed children to become more suicidal and should not be prescribed for them. [3]
Two fourteen-year-old students busted Glaxo for lying about the Vitamin C content of the Ribena drink. [4]
British drug giant GlaxoSmithKline finally admits that thousands of babies in the UK country were inoculated with a batch of toxic whooping cough vaccines in the 1970's. [5]
In September 1992 the Ulverston site (then owned by Glaxo Wellcome) dumped several toxic chemicals in the river Leven, without authorisation. The chemicals included trichloroethylene, chloroform, and chlorobenzene [6]
A new BBC documentary exposes how the city of New York has been forcing HIV-positive children under its supervision to be used as human guinea pigs in tests for experimental AIDS drug trials. GlaxoSmithKline embroiled in unethical clinical trials. [7]
US Senator requests documents from GlaxoSmithKline that highlights the company knew about the Paxil suicide risk in children and adolescents but chose not to go public with its findings [8]
GlaxoSmithKline's Rotavirus vaccine linked to infant deaths [9]
GlaxoSmithKline delayed informing the authorities that a controversial drug increased the likelihood of suicide among teenagers. [10]
A US family awarded $2.5 million (£1.6 million) in damages after a Philadelphia jury decided GlaxoSmithKline's antidepressant Paxil, known as Seroxat in Britain, was responsible for their son's birth defects. [11]
A mass immunisation campaign with a Urabe-containing MMR vaccine was carried out in 1997 in the city of Salvador, NE Brazil, with a target population of children aged 1-11 years. There was an outbreak of aseptic meningitis following the mass campaign in which GlaxoSmithKline's Pluserix was administered. [12]
GlaxoSmithKline Argentina Laboratories Company was fined 400,000 pesos by Judge Marcelo Aguinsky following a report issued by the National Administration of Medicine, Food and Technology (ANMAT in Spanish) for irregularities during lab vaccine trials conducted between 2007 and 2008 that allegedly killed 14 babies. [13]
In the largest settlement involving a pharmaceutical company, the British drugmaker GlaxoSmithKline agreed to plead guilty to criminal charges and pay $3 billion in fines for promoting its best-selling antidepressants for unapproved uses and failing to report safety data about a top diabetes drug [14]
Way to go Jenson!
[1] Smithkline and Rohm & Haas to Clean up Toxic Site [1992 - New York Times]
[2] Jury Awards $6.4 Million In Killings Tied to Drug [2001 - New York Times]
[3] Britain Says Use of Paxil By Children Is Dangerous [2003 - New York Times]
[4] Anna Devathasan and Jenny Suo: The Ribena girls [2007 - New Zealand Herald]
[5] UK babies given toxic vaccines, admits Glaxo [2002 - The Guardian]
[6] North's top polluters named [2002 - BBC News]
[7] Guinea Pig Kids: How New York City is Using Children to Test Experimental AIDS Drugs [2004 - BBC TV]
[8] Sen. Grassley Questions Glaxo on Paxil and Suicide Risk [2008 - Wall Street Journal]
[9] Pneumonia deaths seen with Glaxo vaccine: FDA [2008 - Reuters]
[10] Drugs firms face new laws on test results [2008 - The Guardian]
[11] GSK antidepressant Paxil to blame for baby's heart defects, US jury rules [2009 - The Telegraph]
[12] Outbreak of Aseptic Meningitis associated with Mass Vaccination with a Urabe-containing Measles-Mumps-Rubella Vaccine [2000 - American Journal of Epidemiology, Vol 151, No. 5.]
[13] GSK fined over vaccine trials; 14 babies reported dead [2012 - Buenos Aires Herald]
[14] Glaxo Agrees to Pay $3 Billion in Fraud Settlement [2012 - New York Times]
Labels: F1, Formula One, gsk, Jenson Button, Lucozade, McLaren, Money, Motorsport, Sponsors
First do no harm... providing it's no longer than ...


text:
Knicks agree to terms with Elfrid Payton: 2 years, $16 million
By Stefan Bondy
Elfrid Payton, who has a history with GM Scott Perry, agreed to terms with the Knicks on a two-year, $16 million pact.
The second year is a reported team option.
The 25-year-old point guard, who only played 42 games last season with the Pelicans because of injuries, is big for his position and can create offensively, leading to six triple-doubles in those limited appearances. But he has struggled on defense and has never played for a winning team. On the Knicks, he could compete for a starting spot with point guard Dennis Smith, play alongside him in the backcourt or come off the bench.
Payton will join a crowded but limited Knick backcourt. (Rich Pedroncelli/AP)
The two-guard spot is up for grabs behind RJ Barrett, with Damyean Dotson, Wayne Ellington and Frank Ntilikina in the mix.
Payton was drafted by the Magic in 2014 when Perry was the organization's assistant GM. He was an All-Rookie selection but never quite lived up to the hype.
[More Knicks] Reggie Bullock had spinal surgery on Wednesday (and it's the reason why the Knicks reworked his deal) »
Perry then discussed trading for Payton in 2018, but instead acquired Mudiay. Now Payton is taking the spot of Mudiay, who is an unrestricted free agent.
The Payton pact falls in line with the majority of New York's signings in that it's for two years with a team option for the second, maintaining the club's flexibility for the next two summers.
Latest Knicks
Reggie Bullock had spinal surgery on Wednesday (and it's the reason why the Knicks reworked his deal)

redpajama_set_name: RedPajamaCommonCrawl


Received: November 7, 2016; Revised: December 8, 2016; Accepted: December 2, 2016. Published online: December 31, 2016.
This study investigated removal of radionuclides (Cs, Sr) in surface water by coagulation and precipitation. Jar tests were conducted with various chemical and natural coagulants to remove the stabilized radionuclides (133Cs, 88Sr). Chemical coagulants included aluminum sulfate, poly aluminum chloride, and poly aluminum hydroxide chloride silicate (PACS); natural coagulants (minerals) included illite and zeolite. Chemical coagulant alone could achieve removals of Cs and Sr less than 10%; The removals increased up to 23.1% for Cs and 17.8% for Sr with addition of poly-dimethyldiallylammonium chloride (polyDADMAC) along with the chemical coagulants. Compared with chemical coagulants, natural coagulants (minerals) could achieve higher removals of Cs and Sr. Addition of zeolite along with PACS and polyDADMAC increased the removal rates up to 36.9% for Cs and 17.1% for Sr.


text:
CCTV appeal: Knifeman threatens woman at petrol station
CCTV appeal.
John Deehan
A woman was subjected to a terrifying ordeal when a man brandishing a knife threatened her at a petrol station in Burnley.
Police have released CCTV of a man they want to speak with in relation to the incident, which happened at 6pm last night.
The 22-year-old victim was filling up her car at Tesco petrol station in Centenary Way when she went to pay at the cashier before walking back to her car.
As she got in the driver's door, a man, who was in possession of a knife, got into the passenger seat and told her to drive. The victim screamed, got out of the car and ran to the cashier. The man then left the vehicle and made off on foot along Centenary Way.
DS Paul Barlow, of Burnley CID, said: "This was a frightening incident for the victim who was simply getting back into her car after paying for petrol and an investigation to find the man responsible is under way. We are keen to speak to the man pictured on the CCTV images in connection with our on-going enquiries and I would urge anyone who recognises him or who has any information about this incident to contact us as soon as possible."
Anyone with information can contact police on 101 quoting log 1171 of 11th February. Alternatively Crimestoppers can be contacted, anonymously, on 0800 555 111 or online at Crimestoppers-uk.org.


Praise God and congratulations to the contingent of IPEKA Junior High students who won some medals in Olimpiade Sains Nasional (National Science Olympiad) XI for Junior High School level. The event was held on June 28 – July 4, 2012 in Pontianak, West Kalimantan.
National Science Olympiad is a competition for some subjects for elementary, junior, and senior high students in Indonesia. Before joining the competition, the participants must first pass a series of selections in district and provincial levels.
Congratulations once again to the contingent. Let's celebrate our victory and keep achieving new successes in the future. And keep moving forward.


text:
In Virginia, the Business Community Abandons the Tea Party
I don't know enough about Virginia (or New Jersey or New York City) to have much to say about their elections yesterday. So I was hoping that one of my Virginia friends would come through with a long, thoughtful email about the McAuliffe-Cuccinelli race, which I considered by far the most interesting of last night's races.
In that race, Terry McAuliffe won a close victory even though the polls had him well ahead.1 Does this bode ill for Democrats? Sure, maybe. On the other hand, McAuliffe was an unusually unsympathetic candidate, and Republicans still couldn't beat him in a state that looks increasingly like the country at large. On balance, then, this really seems like bad news for Republicans no matter how they try to spin things.
However, one of my liberal Virginia pals had an interesting take on why Cuccinelli lost:
I agree with Erickson and First Read regarding a lot of the race-specific reasons for Cuccinelli's loss. But, to me, the biggest mistake that Cuccinelli made was his initial tentative step toward making this a Tea Party campaign that downplayed economic messages in favor of his hot buttons — which, by the way, far and away most animated him on the stump (reminiscent of Santorum, almost).
This just doesn't fly with the NoVa business interests. They'll support any right wing crank as long as there is no daylight between them on business interests, taxes, etc. But Cuccinelli had the unnerving tendency to go headlong and unapologetically into his crusades at the expense of all else (e.g., massive and expensive witch hunt against UVA professor for climate change views, unqualified support for anti-abortion and contraception laws, and, of course, leading the doomed Obamacare challenges). In none of his crusades would business benefit in any significant way if he were successful. At the end of the day, he was spending significant resources to prove ideological points. Further, his attempted course corrections at trying to put his economic message front and center just lacked authenticity — more pro forma than passion. The business lobby wants the Governor out there selling Virginia, attracting business and jobs. Cuccinelli just seemed to be the worst salesman for this.
This speaks to all the recent chatter about whether the business wing of the GOP is finally fed up with the tea party and willing to do something about it. The message here isn't that Cuccinelli was anti-business, but simply that he was so plainly animated by crusades on social issues that the business community didn't trust him. They were afraid that at worst he might actively scare away business, and at best he'd never put any real energy into attracting it. McAuliffe, by contrast, is all about attracting business to Virginia. So the usual business-tea party partnership broke down.
I just thought I'd share this. Cuccinelli might be a bit of a unique character, but he's not that unique. The business community might have fired a shot across the tea party bow last night.
1Will this be a boon for the folks who are convinced that mainstream polls are all skewed against conservatives? Maybe!


text: Q: Como puedo realizar la paginación de una tabla con mas de 4000 registros usando post en en lugar de get Como puedo realizar la paginación de una tabla con mas de 4000 registros usando el evento post, eh visto casos con Get, pero no quiero mostrar nada en la URL cada que cambio de paginación

redpajama_set_name: RedPajamaStackExchange


There has been a wave of change coming over the collision industry the last several years and it looks like the tides are finally turning in favor of the repairer and consumer. This wave of change toward original equipment manufacturer (OEM) certifications is one of the most positive changes the collision industry has gone through in recent history.
Some will argue when OEM certification actually started, but we can all agree it is present today and will only become more prevalent in the future.
I see some shops stepping up to the plate and achieving certification through an individual OEM or a third party like Assured Performance, while others are finding OEM repair procedures through ALLDATA Collision or the technical knowledge portal on the I-CAR website. Unfortunately, there are still others that are standing back and hoping that this wave of change doesn't cause the tide to wipe out their sandcastle.
I see OEM certification as a necessity to repair vehicles correctly and I also see OEMs looking for ways to direct customers to certified shops. There are already vehicle communication systems that acknowledge when you are in an accident and offer to call for assistance. So it is safe to say that the next logical step is to contact a certified shop for you.
OEM certification is not easy to get and not all shops will qualify, which is why some are worried that the tide will wipe out their sandcastles. There is vehicle specific training required, special tools, as well as controlled shop layouts and repair areas. I believe those that work towards OEM certification will find it is worth the expense and having it will put them ahead of their competition. A certified shop will be able to recoup their investment through OEM referrals, more control over the repair process and increased labor rates justified by certified repairs.
So how does shop certification affect insurance companies? I say it takes them out of the driver's seat and puts the shop in control of the repair, which is how it should have been all along.
The increasing number of shops becoming OEM certified and the availability of OEM position statements like those found on oem1stop.com allows the shop to become the authority on vehicle repair. As growth toward OEM certification continues, the insurance company scorecard will become less important. There will be more emphasis on the method of repair and OEM compliance than severity and alternative parts usage.
This regained authority cannot be taken lightly; the insurance companies will be looking for ways to obtain control again, so any misuse will give them leverage to challenge the shop. Achieving and maintaining OEM certifications will be the key to sustainability.
I look forward to seeing our industry change with certified shops taking the lead and believe most see it as a welcome transformation. Yes, there will still be "those shops" that will repair a vehicle as they have the last 20 years, but hopefully they too will step up as certified shops become more commonplace. So now the choice is yours, the industry is yours, do you become certified, or will you sit back and watch while the wave of change continues.
John P. Kotter states in his book Leading Change; "The rate of change is not going to slow down anytime soon. If anything, competition in most industries will probably speed up even more in the next few decades." I think that observation fits the collision industry perfectly right now.


The latest breed of smartwatches have a lot of integrated stuff and run on Android OS; the TrueSmart from Omate comes with hardware GPS, can receive and make phone calls, browse the web and many more; we could think it as a fully-featured smartphone disguised as a wristwatch. Let's check the product in more detail now, shall we?
via [M] Omate TrueSmart Smartwatch Review.


This phone repair company had two locations doing business as My Phone Repair and i FIX IT Central. The client wanted a directory listing-type of statically designed mobile responsive website that had a cohesive look on each. The websites are a simple one-page designs that provide the basic information that visitors would need keeping in mind many would be viewing while looking on a mobile device.


SIOUX FALLS, S.D. – The South Dakota Department of Labor partnered with KDLT-TV to host a career fair on Wednesday in downtown Sioux Falls.
Businesses in the Sioux Falls area welcomed career seekers to their stations. State officials say the unemployment rate in Sioux Falls is 2.9%. Rates this low make it more difficult for businesses to find people withe the exact set of skills they seek.
In a market this competitive, federal apprenticeships are now on the rise, and can be beneficial to both employee and employer.
"Doing it themselves. To grow their own talent. And to really commit to a job seeker that I'm going to be a part in your training and get that done. Keep that employee, grow their skills, and have a great employee for many years," says Sioux Falls Job Service Manager Greg Johnson.
41 Businesses took part in the career fair, including Daktronics, Sanford, Avera, and Win Chill, just to name a few.